ECSP055809A - Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 - Google Patents

Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4

Info

Publication number
ECSP055809A
ECSP055809A EC2005005809A ECSP055809A ECSP055809A EC SP055809 A ECSP055809 A EC SP055809A EC 2005005809 A EC2005005809 A EC 2005005809A EC SP055809 A ECSP055809 A EC SP055809A EC SP055809 A ECSP055809 A EC SP055809A
Authority
EC
Ecuador
Prior art keywords
inhibitors
naftiridina
phosphodiesterase
carboxamide
dihydro
Prior art date
Application number
EC2005005809A
Other languages
English (en)
Inventor
Daniel Dube
Michel Gallant
Patrick Lacombe
Renee Aspiotis
Laurence Dube
Yves Girard
Dwight Macdonald
Original Assignee
Merck Frosst Canada Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Inc filed Critical Merck Frosst Canada Inc
Publication of ECSP055809A publication Critical patent/ECSP055809A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Virology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos representados por la Fórmula (I): (I)o una sal farmacéuticamente aceptable de los mismos, son inhibidores de la fosfodiesterasa útiles en el tratamiento de asma e inflamación, y útiles para la intensificación de la cognición.
EC2005005809A 2002-11-22 2005-05-20 Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4 ECSP055809A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42861102P 2002-11-22 2002-11-22

Publications (1)

Publication Number Publication Date
ECSP055809A true ECSP055809A (es) 2005-08-11

Family

ID=32393431

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2005005809A ECSP055809A (es) 2002-11-22 2005-05-20 Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4

Country Status (23)

Country Link
US (2) US7342024B2 (es)
EP (1) EP1565464B1 (es)
JP (1) JP4499571B2 (es)
KR (1) KR20050085112A (es)
CN (1) CN100475813C (es)
AT (1) ATE402175T1 (es)
AU (1) AU2003283167B2 (es)
BR (1) BR0316458A (es)
CA (1) CA2506648C (es)
CL (1) CL2004001050A1 (es)
DE (1) DE60322417D1 (es)
EC (1) ECSP055809A (es)
HR (1) HRP20050451A2 (es)
IS (1) IS7839A (es)
MA (1) MA27566A1 (es)
MX (1) MXPA05005413A (es)
NO (1) NO20053046L (es)
NZ (1) NZ539812A (es)
PL (1) PL377237A1 (es)
RU (1) RU2312865C2 (es)
UA (1) UA82208C2 (es)
WO (1) WO2004048374A1 (es)
ZA (1) ZA200503586B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094874B2 (en) 2000-05-26 2006-08-22 Bristol-Myers Squibb Co. Soluble CTLA4 mutant molecules
JO2311B1 (en) * 2001-08-29 2005-09-12 ميرك فروست كندا ليمتد Alkyl inhibitors Ariel phosphodiesterase-4
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar
WO2007050576A2 (en) * 2005-10-27 2007-05-03 Merck & Co., Inc. A method of preparing a 4-oxo-1- (3 substituted phenyl) -1, 4-dihydro-1, 8-naphthyridine-3- carboxamide phosphodiesterase-4 inhibitor
AR057555A1 (es) * 2005-10-27 2007-12-05 Merck Frosst Canada Ltd Un inhibidor de fosfodiesterasa-4 4-oxo-1-(3-sustituido fenil-1,4-dihidro-1,8-naftiridin-3-carboxamida y un procedimiento de preparacion del mismo
EP2359826B1 (en) 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
PL2074123T3 (pl) * 2006-10-16 2013-04-30 Bionomics Ltd Nowe związki o działaniu przeciwlękowym
US10954231B2 (en) 2006-10-16 2021-03-23 Bionomics Limited Anxiolytic compounds
ATE545417T1 (de) * 2007-03-14 2012-03-15 Ranbaxy Lab Ltd Pyrazoloä3,4-büpyridin-derivate als phosphodiesterasehemmer
CN101641094A (zh) * 2007-04-11 2010-02-03 爱尔康研究有限公司 TNFα抑制剂联合抗组胺药治疗变应性鼻炎和变应性结膜炎的用途
US8563566B2 (en) * 2007-08-01 2013-10-22 Valeant Pharmaceuticals International Naphthyridine derivatives as potassium channel modulators
DK2297106T3 (da) 2008-05-27 2014-10-06 Astrazeneca Ab Phenoxypyridinylamidderivater og deres anvendelse til behandling af pde4-medierede sygdomstilstande
BR112012007091A2 (pt) * 2009-10-01 2016-04-19 Alcon Res Ltd composições de olopatadina e seus usos
WO2012003436A1 (en) * 2010-07-01 2012-01-05 Azevan Pharmaceuticals, Inc. Methods for treating post traumatic stress disorder
AU2012222874B2 (en) 2011-03-02 2015-04-16 Bionomics Limited Novel small-molecules as therapeutics
CA2835450C (en) 2011-05-12 2020-05-12 Bionomics Limited Methods for preparing naphthyridines
US8889730B2 (en) 2012-04-10 2014-11-18 Pfizer Inc. Indole and indazole compounds that activate AMPK
CN104428292B (zh) * 2012-06-15 2017-02-08 生物药品解决方案有限公司 氨基磺酸苯基烷基酯化合物及包含所述化合物的肌肉松弛组合物
CA2905242C (en) 2013-03-15 2016-11-29 Pfizer Inc. Indole compounds that activate ampk
CN106316824B (zh) * 2016-08-18 2018-10-19 广州康瑞泰药业有限公司 一种合成2-氟环丙烷甲酸的新方法
CN110382495B (zh) * 2016-12-16 2022-04-05 基石药业（苏州）有限公司 Cdk4/6抑制剂
MX2021007938A (es) 2018-12-28 2022-01-24 Regeneron Pharma Tratamiento de trastornos respiratorios con inhibidores de la araquidonato 15-lipooxigenasa (alox15).

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2808070A1 (de) * 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US5328908A (en) * 1988-10-24 1994-07-12 Procter & Gamble Pharmaceuticals, Inc. Antimicrobial quinolone thioureas
US5321029A (en) * 1988-11-14 1994-06-14 Beecham-Wuelfing Gmbh & Co.K.G. Xanthines
AU3265695A (en) * 1994-08-29 1996-03-22 Yamanouchi Pharmaceutical Co., Ltd. Novel naphthyridine derivative and medicinal composition thereof
DE69631423T2 (de) * 1995-08-02 2004-12-02 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
ATE222906T1 (de) * 1995-09-22 2002-09-15 Wakunaga Pharma Co Ltd Pyridoncarbonsäurederivate als antibakterielle wirkstoffe
US6297248B1 (en) 1997-04-06 2001-10-02 Suntory Limited 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor
JPH11106385A (ja) * 1997-08-06 1999-04-20 Suntory Ltd Ｉｖ型ホスホジエステラーゼ阻害作用を有する１−アリール−１，８−ナフチリジン−４−オン誘導体
DE59904535D1 (de) * 1998-05-05 2003-04-17 Altana Pharma Ag Neue Benzonaphtyridin-N-oxide
AR029185A1 (es) * 1999-10-25 2003-06-18 Yamanouchi Pharma Co Ltd Derivado de naftiridina
US6794447B1 (en) * 2000-07-28 2004-09-21 Taylor Made Golf Co., Inc. Golf balls incorporating nanocomposite materials
ATE303384T1 (de) 2001-05-24 2005-09-15 Merck Frosst Canada Inc 1-biaryl-1,8-naphthyridin-4-one als phosphodieseterase-inhibitoren
KR100824233B1 (ko) * 2001-10-10 2008-04-24 씨제이제일제당 (주) 사이클로옥시게나제-2의 저해제로서 선택성이 뛰어난3,4-디하이드로-1ｈ-나프탈렌 유도체
IS7839A (is) * 2002-11-22 2004-05-23 Merck Frosst Canada Ltd. 4-oxó-1-(3-setið fenýl-1,4-díhýdró-1,8-naftýridín-3-karboxamíð fosfódíesterasa-4 hindrar

Also Published As

Publication number Publication date
BR0316458A (pt) 2005-10-11
US7238706B2 (en) 2007-07-03
PL377237A1 (pl) 2006-01-23
CA2506648C (en) 2011-01-25
UA82208C2 (en) 2008-03-25
CL2004001050A1 (es) 2005-03-28
KR20050085112A (ko) 2005-08-29
US7342024B2 (en) 2008-03-11
ATE402175T1 (de) 2008-08-15
MXPA05005413A (es) 2005-08-03
NO20053046D0 (no) 2005-06-21
NO20053046L (no) 2005-07-27
US20050107402A1 (en) 2005-05-19
US20060058316A1 (en) 2006-03-16
NZ539812A (en) 2007-12-21
AU2003283167B2 (en) 2009-01-08
CA2506648A1 (en) 2004-06-10
CN100475813C (zh) 2009-04-08
RU2005119644A (ru) 2006-01-20
JP2006508989A (ja) 2006-03-16
DE60322417D1 (en) 2008-09-04
HRP20050451A2 (en) 2006-02-28
JP4499571B2 (ja) 2010-07-07
MA27566A1 (fr) 2005-10-03
WO2004048374A1 (en) 2004-06-10
EP1565464B1 (en) 2008-07-23
IS7839A (is) 2004-05-23
CN1738819A (zh) 2006-02-22
AU2003283167A1 (en) 2004-06-18
ZA200503586B (en) 2006-07-26
RU2312865C2 (ru) 2007-12-20
EP1565464A1 (en) 2005-08-24

Similar Documents

Publication Publication Date Title
ECSP055809A (es) Inhibidores 4-oxo-1-(3-fenil sustituido)-1,4-dihidro-1,8-naftiridina-3-carboxamida de la fosfodiesterasa-4
JO2311B1 (en) Alkyl inhibitors Ariel phosphodiesterase-4
ATE371656T1 (de) Heteroaryl-pyrimidinderivate als jak-inhibitoren
PE20030061A1 (es) 1-biaril-1,8-naftiridin-4-ona como inhibidores de fosfodiesterasa-4
NO20060665L (no) N-substituerte pyrazolyl-amidyl-benzimidazolyl C-kit inhibitorer
HRP20090281T1 (hr) 1,2,3,4-tetrasubstituirani indol za liječenje respiratornih bolesti
IL165262A (en) Kinase inhibitors and pharmaceutical compositions containing them
ATE302775T1 (de) Carbolinderivate
DE60330187D1 (de) Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
EP1689406A4 (en) HETEROCYCLIC INHIBITORS OF MEK AND METHOD FOR THEIR APPLICATION
NO20060670L (no) N3-substituerte imidazopyridin C-kit inhibitorer
GEP20094638B (en) Benzimidazolone carboxylic acid derivatives
ATE346067T1 (de) Carbolinderivate
SG162614A1 (en) Bicyclic 6-alkylidene-penems as beta-lactamases inhibitors
NO20052182L (no) Nye forbindelser
MXPA04006041A (es) Antivirales de piridoquinoxalina.
ATE311389T1 (de) Wirkstoffvorläufer von imidazopyridin-derivaten
ECSP055844A (es) Nuevos compuestos triciclicos
NO20060146L (no) Benzimidazolderivater, sammensetninger som inneholder slike, fremstilling derav og anvendelse derav
NO20044550L (no) Heterotrisyklyl 6-alkaliden-penemer som beta-laktamaseinhibitorer
SE0102058D0 (sv) New Salts II
EA200400877A1 (ru) 2'-гало-3',5'-диалкоксифен-1'-илимино-2-имидазолидиновые производные и их применение для лечения недержания мочи
IS8034A (is) Imídasó[4,5-B]kínólínafleiður og notkun þeirra sem NO-myndunarhemla
DK1541553T3 (da) Indolinforbindelse samt medicinsk anvendelse deraf
WO2003039231A3 (en) Compounds and methods for treating transplant rejection